- Home
- CTRE vs QGEN Comparison
CTRE vs QGEN Comparison
Compare CTRE & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRE | QGEN |
|---|---|---|
| Founded | 2013 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 10.2B |
| IPO Year | 2013 | 1998 |
Fundamental Metrics
Financial Performance| Metric | CTRE | QGEN |
|---|---|---|
| Price | $40.22 | $41.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | $42.40 | ★ $45.76 |
| AVG Volume (30 Days) | 2.8M | ★ 2.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | 3.44% | ★ 7.17% |
| EPS Growth | ★ 96.25 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $476,393,000.00 | N/A |
| Revenue This Year | $5.97 | $8.18 |
| Revenue Next Year | $13.39 | $5.71 |
| P/E Ratio | $113.53 | ★ $24.01 |
| Revenue Growth | ★ 60.79 | N/A |
| 52 Week Low | $30.21 | $32.53 |
| 52 Week High | $43.08 | $57.82 |
Technical Indicators
Market Signals| Indicator | CTRE | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.65 | 64.06 |
| Support Level | $35.82 | $38.80 |
| Resistance Level | $40.61 | $42.33 |
| Average True Range (ATR) | 0.99 | 1.12 |
| MACD | 0.18 | 0.23 |
| Stochastic Oscillator | 63.39 | 66.77 |
Price Performance
Historical ComparisonAbout CTRE CareTrust REIT Inc.
CareTrust REIT Inc is a self-administered, publicly traded REIT engaged in the ownership, acquisition, financing, development, and leasing of skilled nursing, seniors housing, and other healthcare-related properties. The company has one reportable segment consisting of investments in healthcare-related real estate assets. It generates revenues by leasing healthcare-related properties to healthcare operators under triple-net lease arrangements, in which the tenant is solely responsible for property-related costs. The company operates in Domestic and Foreign markets, with the majority of revenue coming from Domestic operations.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).